1. Home
  2. CMND vs SCNI Comparison

CMND vs SCNI Comparison

Compare CMND & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$1.12

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

SCNI

Scinai Immunotherapeutics Ltd.

HOLD

Current Price

$0.76

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMND
SCNI
Founded
2017
2003
Country
Canada
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.5M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
CMND
SCNI
Price
$1.12
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
107.0K
22.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.61
52 Week High
$3.25
$6.18

Technical Indicators

Market Signals
Indicator
CMND
SCNI
Relative Strength Index (RSI) 34.57 42.82
Support Level $0.93 $0.65
Resistance Level $1.27 $0.94
Average True Range (ATR) 0.09 0.09
MACD 0.02 0.00
Stochastic Oscillator 14.29 21.47

Price Performance

Historical Comparison
CMND
SCNI

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: